Source: United States Department of Justice 2
The Department of Justice announced today that it will participate in the Computational Antitrust project, hosted by the Stanford University CodeX Center and created by Professor Thibault Schrepel. The project brings together academics from law, computer science, and economics as well as developers, policymakers, and antitrust agencies from around the world to discuss how technology and automation can improve antitrust enforcement.
Source: United States Department of Justice 2
The Department of Justice’s Antitrust Division announced today that it has completed its review of the proposal by the Institute of International Finance (IIF) to promulgate voluntary guidelines, called the Principles for Debt Transparency (Principles), allowing for public disclosure of information regarding the issuance of sovereign debt. Based on the representations in IIF’s letter request, including its description of certain safeguards, the department has concluded that the principles are unlikely to harm competition. Therefore, the department does not presently intend to challenge IIF’s proposed principles.
Source: United States Department of Justice 2
On Jan. 13, 2021, President Donald J. Trump signed into law the Competitive Health Insurance Reform Act of 2020 (the “Act”), which limits the antitrust exemption available to health insurance companies under the McCarran-Ferguson Act. The Act, sponsored by Rep. Peter DeFazio, passed the House of Representatives on Sept. 21, 2020 and passed the Senate on Dec. 22, 2020.
Source: United States Department of Justice 2
The Justice Department’s Antitrust Division announced today that it has completed its review of a proposed joint patent licensing pool known as the University Technology Licensing Program (UTLP). UTLP is a proposal by participating universities to offer licenses to their physical science patents relating to specified emerging technologies.
Source: United States Department of Justice 2
The Department of Justice announced today that it has no intention to challenge proposed efforts by Baxalta US Inc., Emergent BioSolutions Inc., Grifols Therapeutics LLC, and CSL Plasma Inc. (together, the “Requesting Parties”) to assist the Biomedical Advanced Research and Development Authority (BARDA) in designing quality standards for collecting COVID-19 convalescent plasma.